Colorectal Cancer Clinical Trial
Official title:
The Sensitivity of Scar-biopsies for Residual Colorectal Adenocarcinoma After Endoscopic Resection With Uncertain Radicality
After endoscopic removal of a colorectal polyp that harbors (unexpected) adenocarcinoma, pathology usually can not guarantee a radical resection from an oncological point of view. In such case, additional surgical resection is advised. However, only in 15% of patients, residual adenocarcinoma is found. This study investigates the sensitivity of biopsies from the polypectomy scar for residual adenocarcinoma.
Rationale: colorectal polyps may harbor adenocarcinoma. Numbers are increasing due to the
nationwide colorectal screening program. After endoscopic removal, rescue surgery is often
performed because radicality can not be guaranteed by the pathologist. However, in 85% of
surgical specimen no residual malignancy is found. Given morbidity and mortality associated
with surgery a method to diagnose residual cancer is needed.
Biopsies from the polypectomy site are variably used to reduce the likelihood of residual
tumor at the polypectomy site under these circumstances. However, the sensitivity of such
biopsies is unknown.
Objective: to evaluate the sensitivity of second-look endoscopic biopsies from the
polypectomy site for residual tumor.
Study design: prospective cross-sectional design using a multi-center approach. Study
population: patients planned for rescue surgery for the sole reason of (potentially)
irradical endoscopic resection of a colorectal adenocarcinoma without poor differentiation,
lymphovascular invasion or tumor budding and without other signs of dissemination.
Intervention: endoscopic biopsies from the polypectomy site before operation. Main study
parameters/endpoints: sensitivity of second-look biopsies from the polypectomy site for
residual tumor in the resected bowel and postoperative mortality. Various other factors will
be assessed that might be associated with residual cancer.
Nature and extent of the burden and risks associated with participation and benefit:
Depending on the situation: a): In case a tattoo needs to be done of the polypectomy site, a
second endoscopy is done anyway and taking biopsies (painless) will be of no extra burden;
b): In case no tattoo needs to be done a sigmoidoscopy (lesion distal to the splenic flexure)
or colonoscopy (proximal to the splenic flexure) needs to be arranged for the purpose of this
study. A sigmoidoscopy takes 10-20 minutes. Preparation consists of two enemas. A colonoscopy
takes 20-30 minutes. Preparation consists of drinking 3 litre of MoviPrep®, both usually doe
at home. Notice that the patient has recent experience with colonoscopy. If necessary, both
investigations can be arranged under conscious sedation (the rule in colonoscopy), which also
implies day-care admission. The risk of complications of a second endoscopy is estimated <
1:5000. The benefit of a 2nd colonoscopy is the discovery of new polyps in 10-25% of cases.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |